Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

June 30, 2017

Study Completion Date

December 31, 2017

Conditions

LymphomaMultiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL

autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine

BIOLOGICAL

autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine

BIOLOGICAL

autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine

Trial Locations (1)

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw, Warsaw

All Listed Sponsors

lead

Jan Walewski

OTHER

NCT00937183 - Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma | Biotech Hunter | Biotech Hunter